Miriam Mattoscio

Du Cane Road, W12 0NN
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Journal: Health technology assessment (Winchester, England)

Published: June 29, 2026

Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds.

Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds.

Journal: Neurology

Published: March 06, 2026

Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.

Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.

Journal: Lancet (London, England)

Published: March 23, 2025

PANORAMA: A 2021 Clinician Survey of Treatment Approaches for People With New Diagnoses of Relapsing-Remitting Multiple Sclerosis in the United Kingdom.

PANORAMA: A 2021 Clinician Survey of Treatment Approaches for People With New Diagnoses of Relapsing-Remitting Multiple Sclerosis in the United Kingdom.

Journal: International journal of MS care

Published: January 09, 2025

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.

Journal: BMJ open

Published: September 16, 2024

A recent surge of nitrous oxide misuse around London which merits a public health warning.

A recent surge of nitrous oxide misuse around London which merits a public health warning.

Journal: Postgraduate medical journal

Published: October 03, 2023

ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK.

ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK.

Journal: BMJ open

Published: May 17, 2023

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients.

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients.

Journal: Therapeutic advances in neurological disorders

Published: July 22, 2021

B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies.

B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies.

Journal: Nature reviews. Neurology

Published: April 20, 2021

The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis.

The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis.

Journal: Neurology

Published: October 06, 2017

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Journal: The Cochrane database of systematic reviews

Published: April 26, 2017

Analysis of ageing-associated grey matter volume in patients with multiple sclerosis shows excess atrophy in subcortical regions.

Analysis of ageing-associated grey matter volume in patients with multiple sclerosis shows excess atrophy in subcortical regions.

Journal: NeuroImage. Clinical

Published: July 06, 2016

Showing 1-12 of 16

Last Updated: 09/26/2026